Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures: 2015-2024

  • Ocular Therapeutix's Gains from Sales and Divestitures rose 224.37% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year increase of 224.37%. This contributed to the annual value of $1.3 million for FY2024, which is 224.37% up from last year.
  • According to the latest figures from Q4 2024, Ocular Therapeutix's Gains from Sales and Divestitures is $1.3 million, which was up 224.37% from $393,805 recorded in Q4 2023.
  • Over the past 5 years, Ocular Therapeutix's Gains from Sales and Divestitures peaked at $1.3 million during Q4 2024, and registered a low of $393,805 during Q4 2023.
  • Its 2-year average for Gains from Sales and Divestitures is $835,602, with a median of $835,602 in 2023.
  • Data for Ocular Therapeutix's Gains from Sales and Divestitures shows a peak YoY surged of 224.37% (in 2024) over the last 5 years.
  • Ocular Therapeutix's Gains from Sales and Divestitures (Quarterly) stood at $393,805 in 2023, then skyrocketed by 224.37% to $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q4 2024, $393,805 for Q4 2023, and $28,437 during Q4 2015.